scholarly journals Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder

2009 ◽  
Vol 26 (11) ◽  
pp. 1027-1032 ◽  
Author(s):  
Naomi M. Simon ◽  
Nannette N. Herlands ◽  
Elizabeth H. Marks ◽  
Catherine Mancini ◽  
Andrea Letamendi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Childhood Maltreatment ◽  
Symptom Severity ◽  
And Function

scholarly journals Effectiveness of Acceptance Commitment Therapy (ACT) in Social Anxiety Disorder: Application of a Longitudinal Method for Evaluation of Mediation Role of Acceptance, Cognitive Fusion and Values

2021 ◽  
Author(s):  
Esmail Soltani ◽  
◽  
Seyed Abdolmajid Bahrainian ◽  
Ali Farhoudian ◽  
Abbas Masjedi Arani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Negative Evaluation ◽  
Fear Of Negative Evaluation ◽  
Analysis Of Covariance ◽  
Cognitive Fusion

Objectives: The purpose of the current study was to examine the effectiveness of ACT on symptom severity, fear about negative evaluation, quality of life and mediation role of acceptance, cognitive fusion and value among patients with Social Anxiety Disorder (SAD). Methods: Thirty patients diagnosed with SAD were randomized in the intervention (n=15) or waiting list groups (n=15). The Social Phobia and Anxiety Inventory (SPAI), Brief Fear of Negative Evaluation Scale (BFNE), WHO Quality of Life (WHOQOL), Social Anxiety - Acceptance and Action Questionnaire (SA-AAQ), Cognitive Fusion Questionnaire (CFQ) and Valued Living Questionnaire (VLQ) were administered before, immediately after, and at one month follow up. Repeated measurement design was used in the intervention group to investigate the changes of mediation and outcomes variables in the pretest, during, and post- therapy. Twenty-four patients completed the study. One-way analysis of covariance, Multivariate analysis of covariance and repeated measures was used for analysis. Results: Results showed that there were differences between the intervention and waiting list groups on the severity of symptoms (p=0.001), fear of negative evaluation (p=0.002), and quality of life (p=0.03), as well as in terms of specific measures of SA-AAQ(p=0.001), cognitive fusion (p=0.001), and important section of VLQ(p=0.001). Repeated measurement result showed that acceptance and action of social anxiety and cognitive fusion had a mediating role in the severity of anxiety, fear about negative evaluation, and quality of life. Discussion: Results of the study indicate the effectiveness of ACT for SAD and highlighted mediator contribution acceptance and action and cognitive fusion in severity of social anxiety.

Quality of Life in Social Anxiety Disorder Compared With Panic Disorder and the General Population

2002 ◽  
Vol 53 (6) ◽  
pp. 714-718 ◽  
Author(s):  
Naomi M. Simon ◽  
Michael W. Otto ◽  
Nicole B. Korbly ◽  
Patricia M. Peters ◽  
Despina C. Nicolaou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
General Population ◽  
Panic Disorder ◽  
Social Anxiety Disorder

scholarly journals Childhood maltreatment and social anxiety disorder: implications for symptom severity and response to pharmacotherapy

2011 ◽  
Vol 29 (2) ◽  
pp. 132-139 ◽  
Author(s):  
Laura C. Bruce ◽  
Richard G. Heimberg ◽  
Carlos Blanco ◽  
Franklin R. Schneier ◽  
Michael R. Liebowitz
Keyword(s):  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Childhood Maltreatment ◽  
Symptom Severity

scholarly journals PMH25: SOCIAL ANXIETY DISORDER: EFFECT OF RELAPSE ON COSTS AND QUALITY OF LIFE

2003 ◽  
Vol 6 (3) ◽  
pp. 351
Author(s):  
SA Montgomery ◽  
D Servant ◽  
S Rachidi ◽  
C François
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Disorder Effect

scholarly journals Social anxiety disorder and its impact in undergraduate students at Jazan University, Saudi Arabia

2018 ◽  
Vol 9 (2) ◽  
Author(s):  
Ramzi M. Hakami ◽  
Mohamed S. Mahfouz ◽  
Abdulrahman M. Adawi ◽  
Adeebah J. Mahha ◽  
Alaa J. Athathi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Saudi Arabia ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Undergraduate Students ◽  
Social Life ◽  
Clinical Manifestations ◽  
Quality Life

Although social anxiety disorder (SAD) is a common mental disorder, it is often under diagnosed and under treated. The aim of this study is to assess the prevalence, severity, disability, and quality of life towards SAD among students of Jazan University, Saudi Arabia. A cross-sectional study was conducted among a stratified sample of 500 undergraduate students to identify the prevalence of SAD, its correlates, related disability, and its impact on the quality life. All participants completed the Social Phobia Inventory, Leibowitz Social Anxiety Scale, Sheehan Disability Scale, and the WHO Quality of Life – BREF questionnaire. Of 476 students, 25.8% were screened positive for SAD. About 47.2% of the students had mild symptoms, 42.3% had moderate to marked symptoms, and 10.5% had severe to very severe symptoms of SAD. Students who resulted positive for SAD reported significant disabilities in work, social, and family areas, and this has adversely affected their quality of life as compared to those who screened negative for SAD. Students reported several clinical manifestations that affected their functioning and social life. Acting, performing or giving a talk in front of an audience was the most commonly feared situation. Blushing in front of people was the most commonly avoided situation. Since the present study showed a marked prevalence of SAD among students, increased disability, and impaired quality of life, rigorous efforts are needed for early recognition and treatment of SAD.

Randomised controlled trial of integrated cognitive behavioural treatment and motivational enhancement for comorbid social anxiety and alcohol use disorders

2020 ◽  
pp. 000486742095253
Author(s):  
Lexine A Stapinski ◽  
Claudia Sannibale ◽  
Mirjana Subotic ◽  
Ronald M Rapee ◽  
Maree Teesson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Alcohol Use ◽  
Social Anxiety Disorder ◽  
Alcohol Use Disorder ◽  
Controlled Trial ◽  
Integrated Treatment ◽  
Behavioural Treatment

Objective: Alcohol use disorder and social anxiety disorder are interconnected disorders that commonly co-occur. We report the first trial to assess whether integrated treatment for social anxiety and alcohol use disorder comorbidity improves outcomes relative to standard alcohol-focussed treatment. Method: Participants were recruited to a randomised controlled trial, and randomly allocated to one of two treatments, Integrated ( n = 61) or Control (alcohol-focussed; n = 56). Assessment and treatment session were conducted at two sites in Sydney, Australia. Inclusion criteria were as follows: (1) clinical diagnosis of social anxiety disorder and (2) Diagnosis or sub-clinical symptoms of alcohol use disorder. Diagnoses were determined according to the Diagnostic and Statistical Manual of Mental Disorders (4th ed.). All participants ( n = 117) received 10 sessions of cognitive behavioural treatment and motivational enhancement. The Integrated treatment simultaneously targeted social anxiety disorder, alcohol use disorder and the connections between these disorders. The Control treatment focussed on alcohol use disorder only. Outcomes were assessed at 6-month follow-up, with interim assessments at post-treatment and 3 months. Primary outcomes were social anxiety disorder severity (composite Social Phobia Scale and Social Interaction Anxiety Scale), alcohol use disorder severity (standard drinks per day and Severity of Alcohol Dependence Questionnaire) and quality of life (Short-Form Health survey) was assessed to capture the combined impairment of social anxiety and alcohol use disorder comorbidity. Results: At 6-month follow-up, both conditions showed significant reductions in social anxiety and alcohol use disorder symptoms, and improved quality of life. There was no evidence of between-condition differences for alcohol outcomes, with mean consumption reduced by 5.0 (0.8) and 5.8 (1.0) drinks per day following Alcohol and Integrated treatments, respectively. Integrated treatment achieved greater improvements in social anxiety symptoms (mean difference = −14.9, 95% confidence interval = [−28.1, −1.6], d  = 0.60) and quality of life (mean difference = 7.6, 95% confidence interval = [1.2, 14.0], d  = 0.80) relative to alcohol-focused treatment. Conclusion: These results suggest that integrated social anxiety and alcohol use disorder treatment enhances quality of life and social anxiety disorder symptom improvement, but not alcohol outcomes, compared to treatment focussed on alcohol use disorder alone.

Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis

2020 ◽  
Vol 32 (4) ◽  
pp. 169-176
Author(s):  
Taryn Williams ◽  
Michael McCaul ◽  
Guido Schwarzer ◽  
Andrea Cipriani ◽  
Dan J Stein ◽  
...  
Keyword(s):  
Systematic Review ◽  
Anxiety Disorder ◽  
Social Anxiety ◽  
Social Anxiety Disorder ◽  
Symptom Severity ◽  
Meta Analysis ◽  
Response To Treatment ◽  
Pharmacological Intervention ◽  
Quality Of Evidence

AbstractObjective:The aim of this paper was to provide a systematic review and update on the pharmacotherapy of social anxiety disorder (SAD), including the efficacy and tolerability of these agents, the ranking of interventions, and the grading of results by quality of evidence.Methods:The Common Mental Disorder Controlled Trial Register and two trial registries were searched for randomised controlled trials (RCTs) comparing any pharmacological intervention or placebo in the treatment of SAD. We performed a standard pairwise meta-analysis using a random effects model and carried out a network meta-analysis (NMA) using the statistical package, R. Quality of evidence was also assessed.Results:We included 67 RCTs in the review and 21 to 45 interventions in the NMA. Paroxetine was most effective in the reduction of symptom severity as compared to placebo. Superior response to treatment was also observed for paroxetine, brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline. Higher dropout rates were found for fluvoxamine. Brofaromine, escitalopram, fluvoxamine, paroxetine, pregabalin, sertraline, and venlafaxine performed worse in comparison to placebo for the outcome of dropouts due to adverse events. Olanzapine yielded a relatively high rank for treatment efficacy and buspirone the worse rank for dropouts due to any cause.Conclusion:The differences between drugs and placebo were small, apart from a significant reduction in symptom severity and response for paroxetine. We suggest paroxetine as a first-line treatment of SAD, with the consideration of future research on the drug olanzapine as well as brofaromine, bromazepam, clonazepam, escitalopram, fluvoxamine, phenelzine, and sertraline because we observed a response to treatment.

Sign in / Sign up

Export Citation Format

Share Document